US EditionPublished • loading... • Updated
Citius Oncology (Nasdaq: CTOR) raises $18M at-the-market to fund LYMPHIR
Citius Oncology secured $18 million in funding to support LYMPHIR's commercial launch, targeting a market exceeding $400 million, with proceeds also for working capital.
- On 12/27/2024, Citius Oncology, Inc. closed a registered direct offering for 1,284,404 shares at $1.09 per share, raising approximately $18,000,000.
- To support commercialization, the company said net proceeds will fund LYMPHIR’s launch and working capital, with management estimating the initial market exceeds $400,000,000.
- The financing combined a private placement of 15,229,358 shares and warrants at $1.09, with 1,284,404 unregistered warrants issued, H.C. Wainwright & Co. said.
- Under the registration rights agreement, Citius Oncology, Inc. must file a registration statement covering resale of shares and underlying pre-funded warrants and warrants, which may not be sold in the U.S. without an effective SEC registration or exemption.
- Longer-Term risks include the need for substantial additional funds, and robust intellectual property and pending patents could support Citius Oncology, Inc. 's competitive positioning for LYMPHIR.
Insights by Ground AI
37 Articles
37 Articles
Bennington Banner+35 Reposted by 35 other sources
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the closing of its previously announced registered direct offering with…
Coverage Details
Total News Sources37
Leaning Left3Leaning Right2Center10Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 20%
C 67%
13%
Factuality
To view factuality data please Upgrade to Premium
